Please ensure Javascript is enabled for purposes of website accessibility

Ocugen or CureVac: Which Is More Likely to Double Your Money?

By Adria Cimino - Updated Jun 28, 2021 at 10:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Let's look to the wisdom of crowds.

Before choosing which of these two stocks may double your money, you could examine elements like revenue or profit prospects. But how about trying something different: See what other smart investors are saying about coronavirus vaccine players Ocugen (OCGN 1.41%) and CureVac (CVAC -0.74%).

And the best way to do that is by checking out Motley Fool's CAPS. It's a stock-picking game that harnesses the wisdom of crowds to find winning investments. Thousands of players predict which stocks will beat the S&P 500 -- and which ones won't -- during a particular time frame. The game rates players based on their predictions versus those of others. The number of players who say a stock will outperform determines that particular stock's rating. Importantly, players with high ratings influence a stock's rating more than players with low ratings.

Let's see what CAPS tells us about Ocugen and CureVac's potential to double your money.

A smiling group of individuals gather around a laptop.

Image source: Getty Images.


CAPS rating: 1 out of 5 stars

What investors might be noticing: Ocugen soared more than 700% from December through February. Investors cheered Ocugen's deal to co-commercialize Bharat Biotech's close-to-market vaccine candidate in the U.S. The company more recently said it extended the deal to include co-commercialization rights in Canada as well.

What's holding Ocugen back from a better score: The bad news is Ocugen's decision earlier this month not to pursue Emergency Use Authorization in the U.S. for its vaccine candidate. The U.S. Food and Drug Administration advised the company to take the longer route: filing for traditional approval. Ocugen may gain some points from investors if it wins emergency authorization -- and supply contracts -- from Canada.


CAPS rating: 3 out of 5 stars

What investors might be noticing: Investors have been counting on CureVac to provide the world with another mRNA vaccine, following rivals Pfizer and Moderna. CureVac is testing its candidate in a pivotal phase 2b/3 trial. And it plans on beginning clinical testing on a next-generation candidate in the third quarter.

What's holding CureVac back from a better score: CureVac recently announced its first candidate only showed 47% efficacy in the pivotal trial. If CureVac's next-generation candidate produces stronger efficacy results -- in line with those of its more advanced rivals -- it may win back investor confidence.

Foolish bottom line

One-star stocks may be more likely to double your money in a one-year period. About 43% of CAPS one-star stocks doubled investments or did even better over the past year. That's compared to 27% of three-star stocks. So, if we look only at the CAPS trend to draw a conclusion, one-star stock Ocugen might be the route to doubling your money. Of course, it's important to look at the overall picture. And that shows us Ocugen, due to points mentioned above, remains a high-risk stock. 

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.88 (1.41%) $0.04
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.75 (-0.72%) $0.36
Moderna, Inc. Stock Quote
Moderna, Inc.
$176.78 (3.27%) $5.60
CureVac N.V. Stock Quote
CureVac N.V.
$13.38 (-0.74%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.